My thoughts are that some smaller speculative funds may find 008 success enough to buy-in, plus those in the cap raise will add, however little value for FDA. Retailers who are already in a world of pain will only use it as an opportunity to exit. Competition is a worry. I'd back Novartis over PR and DS, at least from an organisational perspective. Much bigger company, more resources.
Ann: Investor Presentation - $66m Capital Raise, page-62
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 24.0¢ | 22.5¢ | $186.1K | 801.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 33599 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.5¢ | 65498 | 1 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |